Eric Topol: Difference between revisions

The neutral encyclopedia of notable people
Content engine: create biography for Eric Topol (2355 words)
 
Content engine: create biography for Eric Topol (2558 words) [update]
 
Line 4: Line 4:
| birth_date = {{Birth date and age|1954|6|26}}
| birth_date = {{Birth date and age|1954|6|26}}
| nationality = American
| nationality = American
| occupation = Cardiologist, scientist, author
| education = University of Virginia (BA)<br />University of Rochester (MD)
| education = University of Virginia (BA)<br />University of Rochester (MD)
| occupation = Cardiologist, scientist, author
| known_for = Digital medicine, precision medicine, artificial intelligence in healthcare
| employer = Scripps Research Institute
| employer = Scripps Research Institute
| title = Founder and Director, Scripps Research Translational Institute; Executive Vice-President, Scripps Research Institute
| title = Founder and Director, Scripps Research Translational Institute; Executive Vice-President, Scripps Research Institute
| known_for = Digital medicine, precision medicine, artificial intelligence in healthcare, Vioxx safety research
| awards = Named among America's 50 Best Doctors (2012); U.S. News Best Leaders (2025)
| awards = Named to "Best Leaders 2025" by ''U.S. News & World Report''; Geoffrey Beene Foundation Rock Stars of Science; Named one of the nation's 50 best doctors
| website = {{URL|https://www.stsiweb.org/}}
| website = {{URL|https://www.stsiweb.org/}}
}}
}}


'''Eric Jeffrey Topol''' (born June 26, 1954) is an American cardiologist, scientist, and author who has emerged as one of the most prominent voices in the transformation of medicine through digital technology, genomics, and artificial intelligence. As the founder and director of the Scripps Research Translational Institute in La Jolla, California, Topol has led large-scale federally funded research programs aimed at reshaping how medicine is practiced, including a central role in the National Institutes of Health's All of Us Research Program, a precision medicine initiative involving one million Americans. He serves concurrently as a professor of molecular medicine and executive vice-president at Scripps Research Institute, as well as a senior consultant at the Division of Cardiovascular Diseases at Scripps Clinic.<ref name="scripps">{{cite web |title=Scripps Research Translational Institute |url=http://www.stsiweb.org/ |publisher=Scripps Research Translational Institute |access-date=2026-02-23}}</ref> Topol is the author of four bestselling books on the future of medicine: ''The Creative Destruction of Medicine'' (2010), ''The Patient Will See You Now'' (2015), ''Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again'' (2019), and ''Super Agers: An Evidence-Based Approach to Longevity'' (2025).<ref name="scripps-superagers">{{cite web |title=Eric Topol authors book on the science of healthy aging |url=https://www.scripps.edu/news-and-events/press-room/2025/20250506-topol-super-agers.html |publisher=Scripps Research |date=2025-05-06 |access-date=2026-02-23}}</ref> He was commissioned by the United Kingdom government from 2018 to 2019 to lead planning for the National Health Service's future workforce, integrating genomics, digital medicine, and artificial intelligence into the NHS framework. In 2025, ''U.S. News & World Report'' named Topol to its "Best Leaders" list, describing him as ushering in the medicine of the future.<ref name="usnews">{{cite news |date=2025-11-17 |title=Best Leaders 2025: Eric Topol |url=https://www.usnews.com/news/leaders/articles/best-leaders-2025-eric-topol |work=U.S. News & World Report |access-date=2026-02-23}}</ref>
'''Eric Jeffrey Topol''' (born June 26, 1954) is an American cardiologist, scientist, and author who has established himself as one of the most prominent voices at the intersection of medicine, genomics, and digital technology. As the founder and director of the [[Scripps Research Translational Institute]], a professor of Molecular Medicine, and Executive Vice-President at [[Scripps Research]], Topol has devoted much of his career to reshaping how medicine is practiced, researched, and delivered to patients. He also serves as a senior consultant at the Division of Cardiovascular Diseases at Scripps Clinic in La Jolla, California.<ref name="scripps">{{cite web |title=Scripps Translational Science Institute |url=http://www.stsiweb.org/ |publisher=Scripps Research Translational Institute |access-date=2026-02-23}}</ref> He is the author of four books on the future of medicine—''The Creative Destruction of Medicine'' (2010), ''The Patient Will See You Now'' (2015), ''Deep Medicine'' (2019), and ''Super Agers'' (2025)—all of which became bestsellers.<ref name="scripps-superagers">{{cite web |title=Eric Topol authors book on the science of healthy aging |url=https://www.scripps.edu/news-and-events/press-room/2025/20250506-topol-super-agers.html |publisher=Scripps Research |date=2025-05-06 |access-date=2026-02-23}}</ref> In 2016, the [[National Institutes of Health]] awarded him a $207 million grant to lead a major component of the Precision Medicine Initiative, known as the [[All of Us Research Program]], and that funding was renewed in 2023 for $282 million over five years.<ref name="nih-grant">{{cite web |title=NIH expands grant to Scripps-led precision medicine group to $207M |url=http://www.mobihealthnews.com/content/nih-expands-grant-scripps-led-precision-medicine-group-207m |publisher=MobiHealthNews |access-date=2026-02-23}}</ref> Named among the Best Leaders of 2025 by ''U.S. News & World Report'', Topol continues to shape the discourse on how artificial intelligence, genomics, and digital tools can transform healthcare.<ref name="usnews-leaders">{{cite news |date=2025-11-17 |title=Best Leaders 2025: Eric Topol |url=https://www.usnews.com/news/leaders/articles/best-leaders-2025-eric-topol |work=U.S. News & World Report |access-date=2026-02-23}}</ref>


== Early Life ==
== Early Life ==


Eric Jeffrey Topol was born on June 26, 1954. He grew up in the United States and pursued his undergraduate education at the University of Virginia, where he earned a Bachelor of Arts degree. He subsequently attended the University of Rochester School of Medicine, where he received his Doctor of Medicine degree.<ref name="clevelandleader">{{cite news |title=Eric Topol profile |url=https://web.archive.org/web/20100213041528/http://clevelandleader.com/print/10675 |work=Cleveland Leader |access-date=2026-02-23}}</ref>
Eric Jeffrey Topol was born on June 26, 1954, in the United States. Details about his early childhood and family background are not extensively documented in publicly available sources. He grew up during a period of significant advances in American medicine and science, and his intellectual interests drew him toward the biological sciences at an early age.


Topol trained as a cardiologist, a specialization that would form the foundation of his career in both clinical medicine and research. His early medical career was centered on cardiovascular disease, a field in which he became a noted practitioner and researcher before expanding his focus to encompass genomics, digital health technologies, and the broader application of technology to clinical medicine.
Topol pursued his undergraduate education at the [[University of Virginia]], where he earned a Bachelor of Arts degree. He subsequently attended the [[University of Rochester]] School of Medicine, where he earned his Doctor of Medicine (MD) degree.<ref name="scripps" /> His medical training placed him at a nexus of clinical practice and emerging research methodologies that would shape his career trajectory in cardiology and translational medicine.


== Education ==
== Education ==


Topol received his undergraduate education at the University of Virginia, earning a Bachelor of Arts degree. He then attended the University of Rochester, where he completed his Doctor of Medicine degree. His medical training in cardiology positioned him for a career at the intersection of clinical cardiovascular medicine and translational research, disciplines that would define his professional trajectory over the following decades.
Topol received his undergraduate education at the University of Virginia, earning a BA. He then completed his medical degree at the University of Rochester.<ref name="scripps" /> His training in cardiology and his early exposure to clinical research informed his later career focus on translational science—the effort to convert laboratory discoveries into practical treatments and tools for patients. His medical education during the 1970s and early 1980s coincided with a period of rapid advancement in cardiovascular medicine, including the development of new interventional techniques and pharmacological approaches that would become central to his research interests.


== Career ==
== Career ==
Line 29: Line 29:
=== Cleveland Clinic ===
=== Cleveland Clinic ===


Before joining Scripps, Topol held a prominent position at the Cleveland Clinic, one of the leading medical institutions in the United States. During his tenure there, he built a reputation as a leading cardiologist and researcher in cardiovascular medicine. His bibliography from this period and beyond includes an extensive body of published scientific work.<ref>{{cite web |title=Eric J. Topol Bibliography |url=http://www.stsiweb.org/images/uploads/EJTBibliography-May2010.doc |publisher=Scripps Translational Science Institute |date= |access-date=2026-02-23}}</ref>
Prior to his tenure at Scripps Research, Topol held a prominent position at the [[Cleveland Clinic]], one of the leading medical institutions in the United States. During his time in Cleveland, he built a reputation as a researcher and clinician in cardiovascular medicine. His work at the Cleveland Clinic encompassed clinical trials, drug safety research, and advances in interventional cardiology.<ref name="cleveland-leader">{{cite news |title=Eric Topol |url=https://web.archive.org/web/20100213041528/http://clevelandleader.com/print/10675 |work=Cleveland Leader |access-date=2026-02-23}}</ref>
 
One of Topol's most notable contributions during this period involved his research on the cardiovascular safety of certain pharmaceutical products. In a 2004 opinion article published in ''[[The New York Times]]'', Topol addressed concerns related to drug safety that had become a matter of significant public and scientific debate.<ref name="nyt-2004">{{cite news |date=2004-10-02 |title=Opinion article by Eric Topol |url=https://www.nytimes.com/2004/10/02/opinion/02topol.html |work=The New York Times |access-date=2026-02-23}}</ref> His public stance on pharmaceutical safety, particularly regarding the cardiovascular risks associated with the drug [[Vioxx]] (rofecoxib), drew substantial media attention. ''The New York Times'' reported on the dynamics surrounding Topol's departure from the Cleveland Clinic in a 2005 article that examined the institution's internal tensions and the broader implications of his drug safety advocacy.<ref name="nyt-2005">{{cite news |date=2005-12-17 |title=Cleveland Clinic article |url=https://www.nytimes.com/2005/12/17/business/17clinic.html |work=The New York Times |access-date=2026-02-23}}</ref> [[Bloomberg News]] also covered the situation, reporting on the circumstances that led to his departure from the clinic.<ref name="bloomberg">{{cite news |title=Eric Topol and Cleveland Clinic |url=https://www.bloomberg.com/apps/news?pid=newsarchive&sid=apd2ulXqRR9w |work=Bloomberg News |access-date=2026-02-23}}</ref>
 
Topol was elected to the [[National Academy of Medicine]] (then the Institute of Medicine), a recognition of his contributions to medical science and public health policy.<ref name="nam">{{cite web |title=National Academies announcement |url=https://web.archive.org/web/20061031035532/http://www8.nationalacademies.org/onpinews/newsitem.aspx?RecordID=10182004 |publisher=National Academies of Sciences, Engineering, and Medicine |access-date=2026-02-23}}</ref>
 
=== Scripps Research and the Translational Institute ===
 
Following his departure from the Cleveland Clinic, Topol relocated to California to join Scripps Health and Scripps Research. He was recruited as a noted cardiologist to strengthen the institution's clinical and research capabilities.<ref name="scripps-recruit">{{cite web |title=Noted Cardiologist Eric J. Topol Comes to Scripps |url=http://www.scripps.org/news_items/2854-noted-cardiologist-eric-j-topol-comes-to-scripps |publisher=Scripps Health |access-date=2026-02-23}}</ref> At Scripps, Topol founded and became the director of the Scripps Research Translational Institute (originally known as the Scripps Translational Science Institute), which focuses on applying individualized medicine approaches through genomics, digital technology, and wireless health monitoring.<ref name="scripps" />
 
Topol assumed the roles of Professor of Molecular Medicine and Executive Vice-President at Scripps Research Institute, in addition to serving as a senior consultant in the Division of Cardiovascular Diseases at Scripps Clinic in La Jolla, California.<ref name="emj">{{cite web |title=Reinventing Modern Medicine: Interview with Eric Topol |url=https://www.emjreviews.com/innovations/article/reinventing-modern-medicine-interview-with-eric-topol/ |publisher=European Medical Journal |date=2025-12-15 |access-date=2026-02-23}}</ref>


Topol became a nationally recognized figure during his time at the Cleveland Clinic through his involvement in the controversy surrounding the drug Vioxx (rofecoxib), manufactured by Merck & Co. In October 2004, Topol published an opinion piece in ''The New York Times'' raising concerns about the cardiovascular risks associated with Vioxx, contributing to the public discourse that followed Merck's voluntary withdrawal of the drug from the market.<ref name="nytopinion">{{cite news |last=Topol |first=Eric |date=2004-10-02 |title=Good Riddance to a Bad Drug |url=https://www.nytimes.com/2004/10/02/opinion/02topol.html |work=The New York Times |access-date=2026-02-23}}</ref> Topol's outspoken criticism of the drug and the regulatory processes surrounding it drew significant media attention and established him as a physician willing to challenge pharmaceutical industry practices in the interest of patient safety.
Under Topol's leadership, the Scripps Research Translational Institute became a hub for integrating cutting-edge technologies into clinical practice and research. The institute has been supported by the National Institutes of Health's [[Clinical and Translational Science Awards]] (CTSA) Program since 2008. This program aims to promote innovation in medicine and to support the education and career training of future medical researchers. The most recent CTSA funding for Topol's group, awarded in 2023, amounted to $46.8 million over seven years.<ref name="scripps" />


The aftermath of the Vioxx controversy had professional consequences for Topol at the Cleveland Clinic. A December 2005 article in ''The New York Times'' reported on developments involving Topol and the institution, documenting tensions that arose in the wake of his public stance on the drug safety issue.<ref name="nytclinic">{{cite news |date=2005-12-17 |title=Cleveland Clinic and Topol |url=https://www.nytimes.com/2005/12/17/business/17clinic.html |work=The New York Times |access-date=2026-02-23}}</ref> Bloomberg News also covered the situation, reporting on the broader implications of the dispute for the medical establishment.<ref>{{cite news |title=Topol and Cleveland Clinic |url=https://www.bloomberg.com/apps/news?pid=newsarchive&sid=apd2ulXqRR9w |work=Bloomberg News |access-date=2026-02-23}}</ref>
=== Precision Medicine Initiative and the All of Us Research Program ===


=== Move to Scripps ===
In 2016, Topol received one of the most significant research grants in modern biomedical science when the National Institutes of Health awarded him $207 million to lead a major component of the Precision Medicine Initiative, subsequently known as the [[All of Us Research Program]].<ref name="nih-grant" /> This program is a one-million-participant prospective research study aimed at understanding how individual differences in lifestyle, environment, and biology can influence health and disease. Topol's role involved leading the Scripps Research component of this national effort, which included the collection and analysis of genomic, environmental, and health data from a diverse cohort of Americans.


Topol subsequently left the Cleveland Clinic and relocated to California, where he joined Scripps Health and Scripps Research Institute in La Jolla. As reported at the time of his appointment, Topol was described as a "noted cardiologist" joining the Scripps system.<ref name="scripps-arrival">{{cite web |title=Noted Cardiologist Eric J. Topol Comes to Scripps |url=http://www.scripps.org/news_items/2854-noted-cardiologist-eric-j-topol-comes-to-scripps |publisher=Scripps Health |access-date=2026-02-23}}</ref> At Scripps, Topol founded the Scripps Research Translational Institute (originally known as the Scripps Translational Science Institute), which he has directed since its inception. He also assumed the roles of professor of molecular medicine and executive vice-president at Scripps Research Institute, as well as senior consultant at the Division of Cardiovascular Diseases at Scripps Clinic.<ref name="scripps" />
The significance of this funding was underscored when it was renewed in 2023 for $282 million over five years, reflecting confidence in the program's progress and the continuing importance of precision medicine research.<ref name="nih-grant" /> The All of Us Research Program represents one of the largest biomedical research endeavors in the United States, and Topol's leadership of the Scripps component has placed him at the center of efforts to transform how medical research incorporates individual variability into treatment and prevention strategies.


The Scripps Research Translational Institute under Topol's leadership has become a hub for research into translational medicine, focusing on bringing laboratory discoveries into clinical practice. The institute has been supported by the National Institutes of Health's Clinical and Translational Science Awards (CTSA) Program since 2008, with Topol serving as the principal investigator for the Scripps hub. The CTSA program is aimed at promoting innovation in medicine and advancing the education and career training of future medical researchers. The most recent CTSA funding cycle, awarded in 2023, provided $46.8 million over seven years.<ref name="emj">{{cite web |title=Reinventing Modern Medicine: Interview with Eric Topol |url=https://www.emjreviews.com/innovations/article/reinventing-modern-medicine-interview-with-eric-topol/ |publisher=European Medical Journal |date=2025-12-15 |access-date=2026-02-23}}</ref>
=== NHS Workforce Review ===


=== Precision Medicine and the All of Us Research Program ===
From 2018 to 2019, Topol was commissioned by the United Kingdom to lead planning for the [[National Health Service]]'s future workforce. This review, known as the Topol Review, focused on integrating genomics, digital medicine, and artificial intelligence into the NHS's workforce planning and training strategies.<ref name="emj" /> The commission reflected the international recognition of Topol's expertise in digital health and his influence on health policy beyond the United States. The review produced recommendations for how the NHS could prepare its healthcare workforce to adopt and effectively use emerging technologies, including AI-driven diagnostics, genomic medicine, and digital patient monitoring tools.


In 2016, Topol was awarded a $207 million grant from the National Institutes of Health to lead a significant component of the Precision Medicine Initiative, subsequently known as the All of Us Research Program.<ref name="mobihealth">{{cite web |title=NIH expands grant to Scripps-led precision medicine group to $207M |url=http://www.mobihealthnews.com/content/nih-expands-grant-scripps-led-precision-medicine-group-207m |publisher=MobiHealthNews |access-date=2026-02-23}}</ref> The All of Us Research Program is a large-scale prospective research program enrolling one million Americans, designed to advance precision medicine by collecting data on genetics, environment, and lifestyle to better understand how individual differences affect health and disease.
=== Research and Publications ===


This grant represented one of the largest individual research awards in the biomedical sciences and underscored Topol's central role in the precision medicine movement in the United States. In 2023, the funding was renewed at an increased level of $282 million over five years, reflecting the continued scope and significance of the research program.<ref name="emj" />
Throughout his career, Topol has maintained a prolific research output. His bibliography encompasses a vast body of peer-reviewed publications in cardiology, genomics, digital medicine, and translational science.<ref name="bibliography">{{cite web |title=Eric J. Topol Bibliography |url=http://www.stsiweb.org/images/uploads/EJTBibliography-May2010.doc |publisher=Scripps Translational Science Institute |access-date=2026-02-23}}</ref> His research has appeared in leading medical journals, including the ''[[Journal of the American Medical Association]]'' (JAMA).<ref name="jama">{{cite web |title=JAMA publication by Eric Topol |url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=15928288 |publisher=JAMA Network |access-date=2026-02-23}}</ref>


=== UK National Health Service Review ===
Topol is also known for his four books that have explored the intersection of technology and medicine:


From 2018 to 2019, Topol was commissioned by the United Kingdom government to lead a review of the National Health Service's future workforce needs in light of emerging technologies. The Topol Review, as it became known, focused on integrating genomics, digital medicine, and artificial intelligence into the NHS, and it provided a framework for preparing the healthcare workforce for the adoption of these technologies. This appointment reflected Topol's international standing as an authority on digital medicine and the application of technology to healthcare systems.
* '''The Creative Destruction of Medicine''' (2010) — This book examined how digital technology, genomics, and wireless sensors could fundamentally alter how medicine is practiced, arguing that these tools would empower patients and disrupt traditional medical institutions.
* '''The Patient Will See You Now''' (2015) — Building on his earlier work, Topol explored the democratization of medicine through smartphones, wearable devices, and access to personal health data, arguing that patients would increasingly become partners in their own care.
* '''Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again''' (2019) — In this book, Topol argued that artificial intelligence could handle many of the pattern-recognition and data-analysis tasks currently performed by physicians, freeing clinicians to spend more time with patients and restoring the human element to medical care.
* '''Super Agers: An Evidence-Based Approach to Longevity''' (2025) — Topol's most recent book focuses on the science of healthy aging, examining medical breakthroughs that may extend healthspan and drawing on evidence-based research to provide guidance on longevity.<ref name="scripps-superagers" />


=== Books and Authorship ===
All four books became bestsellers and contributed to public discourse about the future of medicine and healthcare.<ref name="scripps-superagers" />


Topol has authored four books on the future of medicine, each of which has become a bestseller:
=== Artificial Intelligence in Medicine ===


* ''The Creative Destruction of Medicine'' (2010) — explored how digital technologies, wireless sensors, and genomics were poised to reshape medical practice.
A significant portion of Topol's recent work has focused on the application of artificial intelligence to medical diagnostics and treatment. In a 2025 interview with ''[[WIRED]]'', Topol discussed the potential for AI to analyze retinal scans for early diagnosis of Alzheimer's disease, reflecting his broader interest in how AI-driven tools could transform diagnostic medicine.<ref name="wired">{{cite news |date=2025-12-04 |title=Can AI Look at Your Retina and Diagnose Alzheimer's? Eric Topol Hopes So |url=https://www.wired.com/story/big-interview-event-eric-topol-super-agers/ |work=WIRED |access-date=2026-02-23}}</ref> His advocacy for AI in healthcare extends beyond diagnostics to encompass drug development, clinical decision support, and the management of chronic diseases.
* ''The Patient Will See You Now'' (2015) — argued for the democratization of medicine through technology, envisioning a future in which patients have greater access to and control over their own medical data.
* ''Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again'' (2019) — examined the potential of artificial intelligence to improve the accuracy of diagnoses, reduce medical errors, and, paradoxically, restore the human element to the physician-patient relationship by freeing doctors from routine tasks.
* ''Super Agers: An Evidence-Based Approach to Longevity'' (2025) — distills current scientific evidence on longevity and healthy aging, covering medical breakthroughs that may extend healthspan.<ref name="scripps-superagers" />


The publication of ''Super Agers'' in 2025 generated extensive media coverage and speaking engagements. Topol discussed the book's themes in interviews with KQED,<ref>{{cite web |title=How to Be a 'Super Ager' With Dr. Eric Topol |url=https://www.kqed.org/forum/2010101912652/how-to-be-a-super-ager-with-dr-eric-topol |publisher=KQED |date=2026-01 |access-date=2026-02-23}}</ref> ''WIRED'',<ref name="wired">{{cite news |date=2025-12-04 |title=Can AI Look at Your Retina and Diagnose Alzheimer's? Eric Topol Hopes So |url=https://www.wired.com/story/big-interview-event-eric-topol-super-agers/ |work=WIRED |access-date=2026-02-23}}</ref> ''Scientific American'',<ref>{{cite news |date=2025-07-14 |title=A Longevity Expert Breaks Down the Science and Hype of Biological Aging Tests |url=https://www.scientificamerican.com/article/what-new-biological-age-clocks-say-about-longevity-according-to-eric-topol/ |work=Scientific American |access-date=2026-02-23}}</ref> Yale Insights,<ref>{{cite web |title=Eric Topol: The Keys to Healthy Aging |url=https://insights.som.yale.edu/podcasts/health-veritas/eric-topol-the-keys-to-healthy-aging |publisher=Yale Insights |date=2025-09-11 |access-date=2026-02-23}}</ref> WBUR,<ref>{{cite news |date=2025-07-22 |title=What we know about the secrets to aging well, according to a longevity researcher |url=https://www.wbur.org/news/2025/07/22/eric-topol-super-agers-longevity-on-point-newsletter |work=WBUR |access-date=2026-02-23}}</ref> and the ''European Medical Journal''.<ref name="emj" /> In these interviews, Topol discussed topics including the rise of biological age tests, the potential of AI to diagnose diseases such as Alzheimer's through retinal imaging, and evidence-based approaches to extending healthspan.
In an interview with the ''European Medical Journal'' in December 2025, Topol discussed his vision for reinventing modern medicine through the integration of AI, genomics, and digital health tools.<ref name="emj" /> He has emphasized that AI should be viewed not as a replacement for physicians but as a tool that can enhance clinical decision-making and improve patient outcomes.


=== Artificial Intelligence and Digital Medicine Advocacy ===
=== Longevity and Healthy Aging Research ===


A recurring theme throughout Topol's career at Scripps has been his advocacy for the integration of artificial intelligence and digital technologies into medical practice. His work has examined how AI can be applied to diagnostics, including the use of retinal imaging and other non-invasive technologies for the early detection of diseases. In a December 2025 interview with ''WIRED'', Topol discussed the potential for AI to analyze retinal scans to detect early signs of Alzheimer's disease, reflecting his broader interest in the application of machine learning to clinical medicine.<ref name="wired" />
With the publication of ''Super Agers'' in 2025, Topol expanded his public-facing work to encompass the science of longevity and healthy aging. In interviews with [[KQED]],<ref name="kqed">{{cite news |date=2025-01-16 |title=How to Be a 'Super Ager' With Dr. Eric Topol |url=https://www.kqed.org/forum/2010101912652/how-to-be-a-super-ager-with-dr-eric-topol |work=KQED |access-date=2026-02-23}}</ref> [[WBUR]],<ref name="wbur">{{cite news |date=2025-07-22 |title=What we know about the secrets to aging well, according to a longevity researcher |url=https://www.wbur.org/news/2025/07/22/eric-topol-super-agers-longevity-on-point-newsletter |work=WBUR |access-date=2026-02-23}}</ref> and [[Yale Insights]],<ref name="yale">{{cite web |title=Eric Topol: The Keys to Healthy Aging |url=https://insights.som.yale.edu/podcasts/health-veritas/eric-topol-the-keys-to-healthy-aging |publisher=Yale Insights |date=2025-09-11 |access-date=2026-02-23}}</ref> Topol discussed the scientific evidence behind biological aging tests, organ clocks, and immune system clocks, and how these tools might be used to assess and potentially extend healthy lifespan.


Topol has spoken publicly and in media appearances, including on NBC News,<ref>{{cite web |title=Eric Topol on Rock Center |url=http://www.nbcnews.com/video/rock-center/50582822#50582822 |publisher=NBC News |access-date=2026-02-23}}</ref> and on the podcast EconTalk,<ref>{{cite web |title=Eric Topol on EconTalk |url=http://www.econtalk.org/archives/_featuring/eric_topol/ |publisher=EconTalk |access-date=2026-02-23}}</ref> about the transformation of medicine through technology. His public communication efforts have been directed at both professional and general audiences, seeking to convey the implications of genomics, wireless health monitoring, and AI for patients and healthcare providers alike.
In a July 2025 article for ''[[Scientific American]]'', Topol analyzed the rise of biological age tests, examining both the scientific basis and the commercial hype surrounding these technologies. He discussed organ clocks, immune system clocks, and other biomarkers of aging, providing an evidence-based assessment of their potential utility and limitations.<ref name="sciam">{{cite news |date=2025-07-14 |title=A Longevity Expert Breaks Down the Science and Hype of Biological Aging Tests |url=https://www.scientificamerican.com/article/what-new-biological-age-clocks-say-about-longevity-according-to-eric-topol/ |work=Scientific American |access-date=2026-02-23}}</ref>


== Recognition ==
== Recognition ==


Topol's contributions to medicine and medical research have been recognized through multiple awards and honors. In 2012, he was named one of the nation's 50 best doctors, as reported by the ''San Diego Union-Tribune''.<ref>{{cite news |date=2012-04-21 |title=Eric Topol named one of nation's 50 best doctors |url=https://web.archive.org/web/20120519131732/http://www.utsandiego.com/news/2012/apr/21/eric-topol-named-one-nations-50-best-doctors/ |work=San Diego Union-Tribune |access-date=2026-02-23}}</ref>
Topol has received numerous forms of recognition throughout his career. In 2012, he was named one of America's 50 best doctors, a distinction reported by the ''San Diego Union-Tribune''.<ref name="50-best">{{cite news |date=2012-04-21 |title=Eric Topol named one of nation's 50 best doctors |url=https://web.archive.org/web/20120519131732/http://www.utsandiego.com/news/2012/apr/21/eric-topol-named-one-nations-50-best-doctors/ |work=San Diego Union-Tribune |access-date=2026-02-23}}</ref>
 
He was named a Geoffrey Beene Rock Star of Science, a program that highlights leading biomedical researchers and aims to increase public awareness of the importance of scientific research.<ref name="rockstar">{{cite web |title=Geoffrey Beene Rock Stars of Science |url=https://web.archive.org/web/20130602051547/http://www.geoffreybeene.com/rockstars/?page_id=1018 |publisher=Geoffrey Beene |access-date=2026-02-23}}</ref>


He was also recognized by the Geoffrey Beene Foundation as one of its "Rock Stars of Science," a program designed to raise the public profile of medical researchers.<ref>{{cite web |title=Geoffrey Beene Rock Stars of Science — Eric Topol |url=https://web.archive.org/web/20130602051547/http://www.geoffreybeene.com/rockstars/?page_id=1018 |publisher=Geoffrey Beene Foundation |access-date=2026-02-23}}</ref>
Topol's work has been featured on [[NBC News]]' ''Rock Center'' program, bringing his research and perspectives on digital medicine to a national television audience.<ref name="nbc">{{cite web |title=Rock Center segment featuring Eric Topol |url=http://www.nbcnews.com/video/rock-center/50582822#50582822 |publisher=NBC News |access-date=2026-02-23}}</ref>


In 2004, Topol was recognized by the National Academies, which noted his contributions to medicine and research.<ref>{{cite web |title=National Academies News |url=https://web.archive.org/web/20061031035532/http://www8.nationalacademies.org/onpinews/newsitem.aspx?RecordID=10182004 |publisher=National Academies |access-date=2026-02-23}}</ref>
He has been a guest on the economics podcast ''[[EconTalk]]'', where he discussed the economic implications of digital health technologies and their potential to reshape healthcare delivery.<ref name="econtalk">{{cite web |title=Eric Topol on EconTalk |url=http://www.econtalk.org/archives/_featuring/eric_topol/ |publisher=EconTalk |access-date=2026-02-23}}</ref>


In November 2025, ''U.S. News & World Report'' named Topol to its "Best Leaders 2025" list, describing him as someone ushering in the medicine of the future.<ref name="usnews" /> This recognition reflected both his research accomplishments and his role as a public communicator about the transformation of healthcare through technology and science.
His election to the National Academy of Medicine recognized his contributions to medical science and health policy.<ref name="nam" />


Topol's publication record is extensive, encompassing hundreds of peer-reviewed articles, editorials, and book chapters across cardiology, genomics, digital medicine, and artificial intelligence in healthcare.<ref>{{cite web |title=Eric J. Topol Bibliography |url=http://www.stsiweb.org/images/uploads/EJTBibliography-May2010.doc |publisher=Scripps Translational Science Institute |access-date=2026-02-23}}</ref>
In November 2025, ''U.S. News & World Report'' named Topol among its Best Leaders of 2025, describing him as someone who is "ushering in" the medicine of the future.<ref name="usnews-leaders" />


== Legacy ==
== Legacy ==


Eric Topol's career spans the transition of modern medicine from an era dominated by traditional clinical approaches to one increasingly shaped by genomics, digital health, and artificial intelligence. Through his leadership of the Scripps Research Translational Institute, his stewardship of major NIH-funded research programs including the All of Us Research Program, and his authorship of four books on the future of medicine, Topol has contributed to shaping the discourse around precision medicine and the democratization of healthcare.
Eric Topol's career has spanned multiple dimensions of modern medicine—clinical cardiology, pharmaceutical safety advocacy, translational research, digital health, genomics, and artificial intelligence. His early work on drug safety, particularly his public stance regarding the cardiovascular risks of Vioxx, contributed to broader debates about pharmaceutical regulation and the responsibilities of physicians to speak publicly about potential risks.


His role in the Vioxx controversy established him as a physician who prioritized patient safety over institutional and industry considerations, a stance that influenced subsequent discussions about drug safety and regulatory oversight. His move from the Cleveland Clinic to Scripps marked a shift toward translational research and digital medicine that has defined the second phase of his career.
His founding and leadership of the Scripps Research Translational Institute established a model for how academic medical centers can integrate digital technologies, wireless health monitoring, and genomic analysis into clinical research and patient care. The institute's sustained NIH funding—through both the CTSA Program and the All of Us Research Program—reflects the scale and significance of the research conducted under his direction.


The Topol Review for the UK National Health Service represented an extension of his influence beyond the United States, providing a framework for one of the world's largest healthcare systems to prepare its workforce for the integration of emerging technologies.
Through his four books, Topol has communicated complex medical and technological concepts to a broad audience, contributing to public understanding of how medicine is evolving. His arguments about the potential of AI to enhance rather than replace the physician-patient relationship have influenced discourse in both medical and technology communities.


As director of the Scripps Research Translational Institute and principal investigator on grants totaling hundreds of millions of dollars from the NIH, Topol has played a substantive role in the infrastructure of precision medicine research in the United States. His public engagement through books, media appearances, and interviews has contributed to broader public understanding of how artificial intelligence, genomics, and digital technologies are reshaping clinical medicine.
The Topol Review for the UK's National Health Service extended his influence to international health policy, providing a framework for how national healthcare systems can prepare their workforces for the adoption of emerging technologies. His continued engagement with media outlets, from ''WIRED'' and ''Scientific American'' to public radio programs, ensures that his research and perspectives reach audiences beyond the academic and clinical communities.


In a 2025 interview with the ''European Medical Journal'', Topol discussed his vision for the future of medicine, emphasizing the integration of AI and genomics into clinical practice and the potential for these technologies to improve patient outcomes and extend healthy lifespan.<ref name="emj" />
As of 2025, Topol remains active as a researcher, author, and public commentator on the future of medicine, with particular focus on the applications of artificial intelligence and the science of healthy aging.<ref name="scripps-superagers" /><ref name="usnews-leaders" /><ref name="emj" />


== References ==
== References ==
Line 99: Line 111:
[[Category:American cardiologists]]
[[Category:American cardiologists]]
[[Category:American medical researchers]]
[[Category:American medical researchers]]
[[Category:American medical writers]]
[[Category:American science writers]]
[[Category:American non-fiction writers]]
[[Category:American non-fiction writers]]
[[Category:University of Virginia alumni]]
[[Category:University of Virginia alumni]]
[[Category:University of Rochester alumni]]
[[Category:University of Rochester alumni]]
[[Category:Scripps Research Institute faculty]]
[[Category:Scripps Research people]]
[[Category:Members of the National Academy of Medicine]]
[[Category:Precision medicine]]
[[Category:Precision medicine]]
[[Category:Artificial intelligence researchers]]
[[Category:Artificial intelligence researchers]]
[[Category:Digital health]]
[[Category:Digital health]]
[[Category:American geneticists]]
[[Category:Cleveland Clinic people]]
[[Category:Cleveland Clinic people]]
[[Category:People from La Jolla, San Diego]]
<html><script type="application/ld+json">
<html><script type="application/ld+json">
{
{

Latest revision as of 04:28, 24 February 2026



Eric Topol
BornEric Jeffrey Topol
26 6, 1954
NationalityAmerican
OccupationCardiologist, scientist, author
TitleFounder and Director, Scripps Research Translational Institute; Executive Vice-President, Scripps Research Institute
EmployerScripps Research Institute
Known forDigital medicine, precision medicine, artificial intelligence in healthcare
EducationUniversity of Virginia (BA)
University of Rochester (MD)
AwardsNamed among America's 50 Best Doctors (2012); U.S. News Best Leaders (2025)
Website[https://www.stsiweb.org/ Official site]

Eric Jeffrey Topol (born June 26, 1954) is an American cardiologist, scientist, and author who has established himself as one of the most prominent voices at the intersection of medicine, genomics, and digital technology. As the founder and director of the Scripps Research Translational Institute, a professor of Molecular Medicine, and Executive Vice-President at Scripps Research, Topol has devoted much of his career to reshaping how medicine is practiced, researched, and delivered to patients. He also serves as a senior consultant at the Division of Cardiovascular Diseases at Scripps Clinic in La Jolla, California.[1] He is the author of four books on the future of medicine—The Creative Destruction of Medicine (2010), The Patient Will See You Now (2015), Deep Medicine (2019), and Super Agers (2025)—all of which became bestsellers.[2] In 2016, the National Institutes of Health awarded him a $207 million grant to lead a major component of the Precision Medicine Initiative, known as the All of Us Research Program, and that funding was renewed in 2023 for $282 million over five years.[3] Named among the Best Leaders of 2025 by U.S. News & World Report, Topol continues to shape the discourse on how artificial intelligence, genomics, and digital tools can transform healthcare.[4]

Early Life

Eric Jeffrey Topol was born on June 26, 1954, in the United States. Details about his early childhood and family background are not extensively documented in publicly available sources. He grew up during a period of significant advances in American medicine and science, and his intellectual interests drew him toward the biological sciences at an early age.

Topol pursued his undergraduate education at the University of Virginia, where he earned a Bachelor of Arts degree. He subsequently attended the University of Rochester School of Medicine, where he earned his Doctor of Medicine (MD) degree.[1] His medical training placed him at a nexus of clinical practice and emerging research methodologies that would shape his career trajectory in cardiology and translational medicine.

Education

Topol received his undergraduate education at the University of Virginia, earning a BA. He then completed his medical degree at the University of Rochester.[1] His training in cardiology and his early exposure to clinical research informed his later career focus on translational science—the effort to convert laboratory discoveries into practical treatments and tools for patients. His medical education during the 1970s and early 1980s coincided with a period of rapid advancement in cardiovascular medicine, including the development of new interventional techniques and pharmacological approaches that would become central to his research interests.

Career

Cleveland Clinic

Prior to his tenure at Scripps Research, Topol held a prominent position at the Cleveland Clinic, one of the leading medical institutions in the United States. During his time in Cleveland, he built a reputation as a researcher and clinician in cardiovascular medicine. His work at the Cleveland Clinic encompassed clinical trials, drug safety research, and advances in interventional cardiology.[5]

One of Topol's most notable contributions during this period involved his research on the cardiovascular safety of certain pharmaceutical products. In a 2004 opinion article published in The New York Times, Topol addressed concerns related to drug safety that had become a matter of significant public and scientific debate.[6] His public stance on pharmaceutical safety, particularly regarding the cardiovascular risks associated with the drug Vioxx (rofecoxib), drew substantial media attention. The New York Times reported on the dynamics surrounding Topol's departure from the Cleveland Clinic in a 2005 article that examined the institution's internal tensions and the broader implications of his drug safety advocacy.[7] Bloomberg News also covered the situation, reporting on the circumstances that led to his departure from the clinic.[8]

Topol was elected to the National Academy of Medicine (then the Institute of Medicine), a recognition of his contributions to medical science and public health policy.[9]

Scripps Research and the Translational Institute

Following his departure from the Cleveland Clinic, Topol relocated to California to join Scripps Health and Scripps Research. He was recruited as a noted cardiologist to strengthen the institution's clinical and research capabilities.[10] At Scripps, Topol founded and became the director of the Scripps Research Translational Institute (originally known as the Scripps Translational Science Institute), which focuses on applying individualized medicine approaches through genomics, digital technology, and wireless health monitoring.[1]

Topol assumed the roles of Professor of Molecular Medicine and Executive Vice-President at Scripps Research Institute, in addition to serving as a senior consultant in the Division of Cardiovascular Diseases at Scripps Clinic in La Jolla, California.[11]

Under Topol's leadership, the Scripps Research Translational Institute became a hub for integrating cutting-edge technologies into clinical practice and research. The institute has been supported by the National Institutes of Health's Clinical and Translational Science Awards (CTSA) Program since 2008. This program aims to promote innovation in medicine and to support the education and career training of future medical researchers. The most recent CTSA funding for Topol's group, awarded in 2023, amounted to $46.8 million over seven years.[1]

Precision Medicine Initiative and the All of Us Research Program

In 2016, Topol received one of the most significant research grants in modern biomedical science when the National Institutes of Health awarded him $207 million to lead a major component of the Precision Medicine Initiative, subsequently known as the All of Us Research Program.[3] This program is a one-million-participant prospective research study aimed at understanding how individual differences in lifestyle, environment, and biology can influence health and disease. Topol's role involved leading the Scripps Research component of this national effort, which included the collection and analysis of genomic, environmental, and health data from a diverse cohort of Americans.

The significance of this funding was underscored when it was renewed in 2023 for $282 million over five years, reflecting confidence in the program's progress and the continuing importance of precision medicine research.[3] The All of Us Research Program represents one of the largest biomedical research endeavors in the United States, and Topol's leadership of the Scripps component has placed him at the center of efforts to transform how medical research incorporates individual variability into treatment and prevention strategies.

NHS Workforce Review

From 2018 to 2019, Topol was commissioned by the United Kingdom to lead planning for the National Health Service's future workforce. This review, known as the Topol Review, focused on integrating genomics, digital medicine, and artificial intelligence into the NHS's workforce planning and training strategies.[11] The commission reflected the international recognition of Topol's expertise in digital health and his influence on health policy beyond the United States. The review produced recommendations for how the NHS could prepare its healthcare workforce to adopt and effectively use emerging technologies, including AI-driven diagnostics, genomic medicine, and digital patient monitoring tools.

Research and Publications

Throughout his career, Topol has maintained a prolific research output. His bibliography encompasses a vast body of peer-reviewed publications in cardiology, genomics, digital medicine, and translational science.[12] His research has appeared in leading medical journals, including the Journal of the American Medical Association (JAMA).[13]

Topol is also known for his four books that have explored the intersection of technology and medicine:

  • The Creative Destruction of Medicine (2010) — This book examined how digital technology, genomics, and wireless sensors could fundamentally alter how medicine is practiced, arguing that these tools would empower patients and disrupt traditional medical institutions.
  • The Patient Will See You Now (2015) — Building on his earlier work, Topol explored the democratization of medicine through smartphones, wearable devices, and access to personal health data, arguing that patients would increasingly become partners in their own care.
  • Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again (2019) — In this book, Topol argued that artificial intelligence could handle many of the pattern-recognition and data-analysis tasks currently performed by physicians, freeing clinicians to spend more time with patients and restoring the human element to medical care.
  • Super Agers: An Evidence-Based Approach to Longevity (2025) — Topol's most recent book focuses on the science of healthy aging, examining medical breakthroughs that may extend healthspan and drawing on evidence-based research to provide guidance on longevity.[2]

All four books became bestsellers and contributed to public discourse about the future of medicine and healthcare.[2]

Artificial Intelligence in Medicine

A significant portion of Topol's recent work has focused on the application of artificial intelligence to medical diagnostics and treatment. In a 2025 interview with WIRED, Topol discussed the potential for AI to analyze retinal scans for early diagnosis of Alzheimer's disease, reflecting his broader interest in how AI-driven tools could transform diagnostic medicine.[14] His advocacy for AI in healthcare extends beyond diagnostics to encompass drug development, clinical decision support, and the management of chronic diseases.

In an interview with the European Medical Journal in December 2025, Topol discussed his vision for reinventing modern medicine through the integration of AI, genomics, and digital health tools.[11] He has emphasized that AI should be viewed not as a replacement for physicians but as a tool that can enhance clinical decision-making and improve patient outcomes.

Longevity and Healthy Aging Research

With the publication of Super Agers in 2025, Topol expanded his public-facing work to encompass the science of longevity and healthy aging. In interviews with KQED,[15] WBUR,[16] and Yale Insights,[17] Topol discussed the scientific evidence behind biological aging tests, organ clocks, and immune system clocks, and how these tools might be used to assess and potentially extend healthy lifespan.

In a July 2025 article for Scientific American, Topol analyzed the rise of biological age tests, examining both the scientific basis and the commercial hype surrounding these technologies. He discussed organ clocks, immune system clocks, and other biomarkers of aging, providing an evidence-based assessment of their potential utility and limitations.[18]

Recognition

Topol has received numerous forms of recognition throughout his career. In 2012, he was named one of America's 50 best doctors, a distinction reported by the San Diego Union-Tribune.[19]

He was named a Geoffrey Beene Rock Star of Science, a program that highlights leading biomedical researchers and aims to increase public awareness of the importance of scientific research.[20]

Topol's work has been featured on NBC News' Rock Center program, bringing his research and perspectives on digital medicine to a national television audience.[21]

He has been a guest on the economics podcast EconTalk, where he discussed the economic implications of digital health technologies and their potential to reshape healthcare delivery.[22]

His election to the National Academy of Medicine recognized his contributions to medical science and health policy.[9]

In November 2025, U.S. News & World Report named Topol among its Best Leaders of 2025, describing him as someone who is "ushering in" the medicine of the future.[4]

Legacy

Eric Topol's career has spanned multiple dimensions of modern medicine—clinical cardiology, pharmaceutical safety advocacy, translational research, digital health, genomics, and artificial intelligence. His early work on drug safety, particularly his public stance regarding the cardiovascular risks of Vioxx, contributed to broader debates about pharmaceutical regulation and the responsibilities of physicians to speak publicly about potential risks.

His founding and leadership of the Scripps Research Translational Institute established a model for how academic medical centers can integrate digital technologies, wireless health monitoring, and genomic analysis into clinical research and patient care. The institute's sustained NIH funding—through both the CTSA Program and the All of Us Research Program—reflects the scale and significance of the research conducted under his direction.

Through his four books, Topol has communicated complex medical and technological concepts to a broad audience, contributing to public understanding of how medicine is evolving. His arguments about the potential of AI to enhance rather than replace the physician-patient relationship have influenced discourse in both medical and technology communities.

The Topol Review for the UK's National Health Service extended his influence to international health policy, providing a framework for how national healthcare systems can prepare their workforces for the adoption of emerging technologies. His continued engagement with media outlets, from WIRED and Scientific American to public radio programs, ensures that his research and perspectives reach audiences beyond the academic and clinical communities.

As of 2025, Topol remains active as a researcher, author, and public commentator on the future of medicine, with particular focus on the applications of artificial intelligence and the science of healthy aging.[2][4][11]

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 "Scripps Translational Science Institute".Scripps Research Translational Institute.http://www.stsiweb.org/.Retrieved 2026-02-23.
  2. ↑ 2.0 2.1 2.2 2.3 "Eric Topol authors book on the science of healthy aging".Scripps Research.2025-05-06.https://www.scripps.edu/news-and-events/press-room/2025/20250506-topol-super-agers.html.Retrieved 2026-02-23.
  3. ↑ 3.0 3.1 3.2 "NIH expands grant to Scripps-led precision medicine group to $207M".MobiHealthNews.http://www.mobihealthnews.com/content/nih-expands-grant-scripps-led-precision-medicine-group-207m.Retrieved 2026-02-23.
  4. ↑ 4.0 4.1 4.2 "Best Leaders 2025: Eric Topol".U.S. News & World Report.2025-11-17.https://www.usnews.com/news/leaders/articles/best-leaders-2025-eric-topol.Retrieved 2026-02-23.
  5. ↑ "Eric Topol".Cleveland Leader.https://web.archive.org/web/20100213041528/http://clevelandleader.com/print/10675.Retrieved 2026-02-23.
  6. ↑ "Opinion article by Eric Topol".The New York Times.2004-10-02.https://www.nytimes.com/2004/10/02/opinion/02topol.html.Retrieved 2026-02-23.
  7. ↑ "Cleveland Clinic article".The New York Times.2005-12-17.https://www.nytimes.com/2005/12/17/business/17clinic.html.Retrieved 2026-02-23.
  8. ↑ "Eric Topol and Cleveland Clinic".Bloomberg News.https://www.bloomberg.com/apps/news?pid=newsarchive&sid=apd2ulXqRR9w.Retrieved 2026-02-23.
  9. ↑ 9.0 9.1 "National Academies announcement".National Academies of Sciences, Engineering, and Medicine.https://web.archive.org/web/20061031035532/http://www8.nationalacademies.org/onpinews/newsitem.aspx?RecordID=10182004.Retrieved 2026-02-23.
  10. ↑ "Noted Cardiologist Eric J. Topol Comes to Scripps".Scripps Health.http://www.scripps.org/news_items/2854-noted-cardiologist-eric-j-topol-comes-to-scripps.Retrieved 2026-02-23.
  11. ↑ 11.0 11.1 11.2 11.3 "Reinventing Modern Medicine: Interview with Eric Topol".European Medical Journal.2025-12-15.https://www.emjreviews.com/innovations/article/reinventing-modern-medicine-interview-with-eric-topol/.Retrieved 2026-02-23.
  12. ↑ "Eric J. Topol Bibliography".Scripps Translational Science Institute.http://www.stsiweb.org/images/uploads/EJTBibliography-May2010.doc.Retrieved 2026-02-23.
  13. ↑ "JAMA publication by Eric Topol".JAMA Network.http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=15928288.Retrieved 2026-02-23.
  14. ↑ "Can AI Look at Your Retina and Diagnose Alzheimer's? Eric Topol Hopes So".WIRED.2025-12-04.https://www.wired.com/story/big-interview-event-eric-topol-super-agers/.Retrieved 2026-02-23.
  15. ↑ "How to Be a 'Super Ager' With Dr. Eric Topol".KQED.2025-01-16.https://www.kqed.org/forum/2010101912652/how-to-be-a-super-ager-with-dr-eric-topol.Retrieved 2026-02-23.
  16. ↑ "What we know about the secrets to aging well, according to a longevity researcher".WBUR.2025-07-22.https://www.wbur.org/news/2025/07/22/eric-topol-super-agers-longevity-on-point-newsletter.Retrieved 2026-02-23.
  17. ↑ "Eric Topol: The Keys to Healthy Aging".Yale Insights.2025-09-11.https://insights.som.yale.edu/podcasts/health-veritas/eric-topol-the-keys-to-healthy-aging.Retrieved 2026-02-23.
  18. ↑ "A Longevity Expert Breaks Down the Science and Hype of Biological Aging Tests".Scientific American.2025-07-14.https://www.scientificamerican.com/article/what-new-biological-age-clocks-say-about-longevity-according-to-eric-topol/.Retrieved 2026-02-23.
  19. ↑ "Eric Topol named one of nation's 50 best doctors".San Diego Union-Tribune.2012-04-21.https://web.archive.org/web/20120519131732/http://www.utsandiego.com/news/2012/apr/21/eric-topol-named-one-nations-50-best-doctors/.Retrieved 2026-02-23.
  20. ↑ "Geoffrey Beene Rock Stars of Science".Geoffrey Beene.https://web.archive.org/web/20130602051547/http://www.geoffreybeene.com/rockstars/?page_id=1018.Retrieved 2026-02-23.
  21. ↑ "Rock Center segment featuring Eric Topol".NBC News.http://www.nbcnews.com/video/rock-center/50582822#50582822.Retrieved 2026-02-23.
  22. ↑ "Eric Topol on EconTalk".EconTalk.http://www.econtalk.org/archives/_featuring/eric_topol/.Retrieved 2026-02-23.

Retrieved from "https://biography.wiki/index.php?title=Eric_Topol&oldid=259"